MarketInOut Stock Screener Log In | Sign Up

Arbutus Biopharma Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 11/03/2026 13:40
Arbutus Biopharma Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization645.29 mln
Float153 mln
Earnings Date11/11/2026

EPS

0.79
Decent

P / E

4.98
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

1-Year Forecast

5.46
Strong upside

Relative Strength

19 / 100
Significantly lagging

Debt / Equity

0.01
Debt-free

Business Description

Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.

Key Fundamentals

EPS0.79
P/E4.98
ROE101
RPS0.94
ROIC200
ROA90.37
Interest Cover1,940
EBITDA, mln153
EV / EBITDA4.96
EV / EBIT4.96
Revenue, mln182
EV / Revenue4.18

Quote Details

Last 3.94
Change -0.06 (-1.5%)
Open 4.01
Volume 913,059
Turnover 3,597,452
Average Volume 2,818,721

Financial Ratios

Pre-Tax Profit Margin84
Leverage Ratio1.06
Current Ratio81.42
Price / Book3.27
Price / Tangible Book3.27
Debt / Equity0.01
Price / Sales4.62
PEG Ratio0.24

Financial Strength

Altman Z-Score30.13
Piotroski F-Score 6 / 9
Price to Graham Number0.90
1-Year Target Price5.46
Short Ratio3.22
Short % of Float27.75

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -8.16% 16 / 100   
1 Month -15.63% 24 / 100   
2 Months -8.16% 33 / 100   
6 Months -10.45% 36 / 100   
1 Year -16.7% 32 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog